報價延遲最少15分鐘:2025/07/17 16:44 EDT
盤後時段
|
||||
|
4.96 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-8.79/-2.82
|
|
企業價值
1.55B
|
| 資產負債 |
|
每股賬面淨值
9.49
|
| 現金流量 |
|
現金流量率
0.37
|
| 損益表 |
|
收益
2.70B
|
|
每股收益
34.03
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 16:44 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
